Home / News

In reponse to report of Commercial Times on Oct. 24, 2021


Date of announcement: 2021/10/25

Time of announcement: 11:52:25

Subject:In reponse to report of Commercial Times on Oct. 24, 2021
Date of events: 2021/10/25

To which item it meets: paragraph 53

1.Date of occurrence of the event:2021/10/25

2.Company name:TSH Biopharm

3.Relationship to the Company (please enter ”head office” or
  ”subsidiaries”): Head office

4.Reciprocal shareholding ratios:N/A

5.Name of the reporting media:Commercial Times

6.Content of the report:
Headline of Commercial Times:”TSH won the patent lawsuit against Merck
Sharp & Dohme” TSH (8432) announced on 10/24 that they won their patent
lawsuit for new drug RETA19 against Merck Sharp & Dohme. TSH said that
it was because one of the ingredients of RETA19 similar to MSD's product.
Although when applying for the launch, TSH made a statement of
non-infringement(P4) to MSD's patent per related regulations. MSD remained
to file the lawsuit and tried to stop RETA19 from being registrated for
drug license.

7.Cause of occurrence: Received an inquiry from Taipei Exchange and explained
based on the above description.

8.Countermeasures: TSH's new drug for hyperlipidemia was applied for
registration on 2020/9/1. Merck Sharp & Dohme filed a patent infringement
lawsuit against TSH according to Pharmaceutical Affairs Act on 2020/12/7.
They tried to affect the launch of the competitor's product through filing
a lawsuit.And it was common. On 2021/10/22, Intellectual Property and
Commercial Court decided in favor of TSH. The Company will apply for
National Health Insurance Drug Price subsequently.
The lawsuit has no impact on the Company's finance.

9.Any other matters that need to be specified:None.